Earnings release
Page 1
RNS Number : 1986R Craneware plc 16 July 2025 Craneware plc("Craneware" or the "Company") FY25 Trading UpdateStrong revenue growth and profitability ahead of expectations - accelerating EBITDA, ARR and NRR 16 July 2025 - Craneware (AIM: CRW.L), a leader in healthcare financial performance solutions, is pleased to provide anupdate on trading for the year ended 30 June 2025 ("FY25"). The Group has experienced positive trading throughout the fiscal year, delivering continued strong growth, and profitabilityahead of consensus market expectations. Subject to audit, the Board expects a 12% increase in adjusted EBITDA to over $65m (FY24: $58.3m) delivered by revenuegrowth of 9% to $205.7m (FY24: $189.3m). Annual Recurring Revenue ("ARR ) has grown by approximately 7% toc.$184m (FY24: $172.0m). This follows continued sales momentum and the transition of an initial proportion of TrisusPlatform Partner revenues associated with the Group's 340B software offerings into recurring revenue streams, as anticipated.Net Revenue Retention has increased to 107% (FY24: 98%). The Group continues to deliver high levels of operating cash conversion, which have been used to invest in the productportfolio, reduce debt and interest costs, with total bank debt reduced to $27.7m (FY24: $35.4m), whilst retaining healthy totalcash reserves of $55.9m (FY24: $34.6m). Outlook The Group anticipates that the ongoing drive within US healthcare to improve efficiency and deliver value in healthcare willcontinue to provide a positive market environment for Craneware's offerings. The partnership with Microsoft is progressing well, raising the profile of The Craneware Group and its AI-powered Trisusofferings with hospital CIOs across the US, providing the basis for increased market penetration in future periods. AIdevelopment in conjunction with Microsoft continues as planned. Currently, a significant proportion of the Platform Partner revenue stream reported is delivered from the Group's 340Bassociated "Shelter" offering. This offering is based on current Craneware software and demonstrates how the Group isproving successful at identifying new ways to utilise its extensive data sets for the benefit of its customers. This programmecontinues to see strong uptake across the 340B customer base and provides a strong backlog as the Group enters FY26. In addition, the Trisus Platform Partner revenue stream also included initial third-party partner offerings. The Companycontinues to evaluate a number of additional third-party partner offerings that can be hosted on the Trisus platform, withanother that was signed before the year end expected to go live in H1 FY26. The continued acceleration in EBITDA, ARR and NRR provides the Board with confidence in the delivery of an acceleratedrevenue growth rate in FY26. The strength of the Company's balance sheet and strong cash generation provide Cranewarewith solid foundations as it executes on its growth strategy, capitalising on its strategic position at the heart of the UShealthcare market. Notice of Results Craneware will announce results for the year ended 30 June 2025 on 15 September 2025. Keith Neilson, CEO of Craneware plc, commented, "We are pleased to see our growth rates accelerating and profitability exceed expectations, with this year's performancesupporting a move to sustainable, double-digit growth. Our extensive data sets and the powerful insights we can provide viaour Trisus platform give our customers the means they need to improve their operational and financial performance. We havea unique capability to support our customers in their missions, and are seeing this translate into continued strong expansionsales within our customer base and a significant and growing base of recurring SaaS revenues. With continued strong cashgeneration, and a strategic position as a source of independent data and insights at the heart of the US healthcare market, weare excited by the opportunity ahead, for us and our customers, and look to the future with confidence." Adjusted EBITDA refers to earnings before interest, tax, depreciation, amortisation, share based payments and exceptional costs. Annual Recurring Revenue ("ARR") includes the annual value of licence and transaction revenues as at 30 June 2025 that are subject tounderlying contracts. For further information, please contact: Craneware plc +44 (0)131 550 3100Keith Neilson, CEOCraig Preston, CFO Close 1 2" 12 Supplied by © Terms of Service| Cookie Policy 2025-07-17 16:25 FY25 Trading Update https://tools.eurolandir.com/tools/Pressreleases/GetPressRelease/?ID=7749715&lang=en-GB&companycode=uk-crw&v= 1/2
Page 2
Alma Strategic Communications (Financial PR) +44 (0)20 3405 0205Caroline Forde, Kinvara Verdon, Sarah Peters craneware@almastrategic.com Peel Hunt (NOMAD and Joint Broker) +44 (0)20 7418 8900Neil Patel, Benjamin Cryer, Kate Bannatyne Investec Bank PLC (Joint Broker) +44 (0)20 7597 5970Patrick Robb, Virginia Bull, James Smith Berenberg (Joint Broker) +44 (0)20 3207 7800Mark Whitmore, Richard Andrews, Patrick Dolaghan This announcement contains inside information as stipulated under the UK version of the Market Abuse Regulation No596/2014 which is part of English Law by virtue of the European (Withdrawal) Act 2018, as amended. On publication of thisannouncement via a Regulatory Information Service, this information is considered to be in the public domain. About The Craneware Group For over 25 years, The Craneware Group (AIM:CRW.L) has been a leader in healthcare financial and operationaltransformation, delivering cutting-edge technologies that drive measurable impact. Our Trisus cloud ecosystem unifies data,revenue intelligence, margin intelligence, and advanced analytics, enabling healthcare organizations to optimize performance,improve financial sustainability, and drive strategic growth. As a trusted Microsoft partner, we provide future-ready solutions-including the Best in KLAS Trisus Chargemaster-thatsimplify the complexities of healthcare finance and operations. What sets us apart is our unique combination of deephealthcare expertise and engineering excellence, positioning us as a strategic partner rather than just a technology provider. The Craneware Group empowers healthcare organizations to achieve sustainable financial success while delivering betteroutcomes for the communities they serve-today and in the future. Together, we are transforming the business of healthcare. Learn more at www.thecranewaregroup.com This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com. RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy. END TSTPKPBKCBKDKOD Close ® Supplied by © Terms of Service| Cookie Policy 2025-07-17 16:25 FY25 Trading Update https://tools.eurolandir.com/tools/Pressreleases/GetPressRelease/?ID=7749715&lang=en-GB&companycode=uk-crw&v= 2/2